Second quarter 2025 total revenue of $141.1 million, including BRIUMVI U.S. net revenue of$138.8 million Raises full year 2025 BRIUMVI U.S. net revenue target to approximately $570 -$575 million Conference call to be held today, Monday, August 4, 2025, at 8:30 AM ET NEW YORK, Aug. 04, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) (the Company or TG Therapeutics) today announced its financial results for the second quarter of 2025, along with recent company developments, and provided an upd ...